Compare AstraZeneca plc (AZN) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs IONQ Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while IONQ Inc trades at $44.74 (market cap $17.60B). The key difference: AstraZeneca plc is far larger — about 14.1× IONQ Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| AZN | IONQ | |
|---|---|---|
Market Cap | $248.14B | $17.60B |
Sector | Health | Technology |
52-Week High | $209.48 | $82.09 |
52-Week Low | $147.06 | $26.59 |
Enterprise Value | $275.41B | $15.53B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
IONQ trades at $45.20, up 6.28% today, with a bullish technical signal from moving averages and strong resistance near $46. The company reported Q2 2026 revenue growth of 287% to $80.1 million, though it missed EPS estimates. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism on quantum computing leadership.
Outlook is growth-driven but high-risk; revenue is projected to double in 2026, yet net losses exceed $1.4 billion. Key risks include profitability timeline, cash burn, and competitive pressures. Upside hinges on execution of its quantum roadmap and defense contracts, but volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
